Russian Federation
Taking into account the growing interest of the pharmaceutical industry in peptide drugs, current trends in the development of the pharmaceutical market in the Russian Federation have been identified. The article presents the advantages and disadvantages of peptide drugs, as well as the features of their use in clinical practice. Modern approaches to increasing the pharmacological activity of peptide drugs and the results of studies confirming the effectiveness of these methods are considered.
peptide drugs, protective groups, pharmacodynamics, pharmacokinetics, modification of a peptide molecule
1. Bulgakov S.A. Geksapeptid dalargin v klinicheskoy gastroenterologii: 30-letniy opyt ispol'zovaniya preparata / S.A. Bulgakov // Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. – 2016. – T. 26, № 3. – S. 103-112. – DOI:https://doi.org/10.22416/13824376-2016-26-3-103-112.
2. Zhuykova S.E. Gliproliny — regulyatornye peptidy s integrativnym deystviem / S.E. Zhuykova // Integrativnaya fiziologiya. – 2020. – T. 1, № 4. – S. 303–316. – DOI:https://doi.org/10.33910/2687-1270-2020-1-4-303-316.
3. Issledovanie farmakokinetiki i biodostupnosti v sozdanii novyh original'nyh lekarstvennyh sredstv peptidnoy struktury i ih optimal'nyh lekarstvennyh form / E.V. Ivannikova, V.P. Zherdev, S.S. Boyko i dr. // Farmakokinetika i farmakodinamika. – 2013. – № 2. – S. 1–17.
4. Polyanskiy M.A. Osnovnye koncepcii sinteza peptidov kak novogo pokoleniya biologicheski aktivnyh preparatov / M.A. Polyanskiy, A.I. Ginak // Izvestiya CanktPeterburgskogo gosudarstvennogo tehnologicheskogo instituta (tehnicheskogo universiteta). – 2021. – № 58 (84). – S. 62–65.
5. Slominskiy, P.A. Peptidnye lekarstvennye sredstva: vozmozhnosti, perspektivy i ogranicheniya / P.A. Slominskiy, M.I. Shadrina // Molekulyarnaya genetika, mikrobiologiya i virusologiya. – 2018. – T. 36, № 1. – S. 8–14. – DOI:https://doi.org/10.18821/0208-06132018-36-1-8-14.
6. Havinson V.H. Lekarstvennye peptidnye preparaty: proshloe, nastoyaschee, buduschee / V.H. Havinson // Klinicheskaya medicina. – 2020. – № 98 (3). – S. 165–177. – DOIhttps://doi.org/10.30629/0023-2149-2020-98-3-165-177.
7. An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor / E.H. Cho, J.C. Lim, S.Y. Lee, S.H. Jung // Journal of Pharmacological Sciences. – 2016. – № 131 (3). – P. 209–214. – DOI:https://doi.org/10.1016/j.jphs.2016.06.006.
8. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives / A. Muheem, F. Shakeel, M.A. Jahangir, M. Anwar et al. // Saudi Pharmaceutical Journal. – 2016. – № 24 (4). – P. 413–428. – DOI:https://doi.org/10.1016/j.jsps.2014.06.004.
9. Development and testing of solid dose formulations containing polysialic acid insulin conjugate: next generation of long-acting insulin / R. Zhang, S. Jain, M. Rowland et al. // Journal of Diabetes Science and Technology. – 2010. – № 4 (3). – P. 532–539. – DOI:https://doi.org/10.1177/193229681000400305.
10. Development of peptide Biopharmaceuticals in Russia / V.I. Deigin, E.A. Poluektova, A.G. Beniashvili et al. // Pharmaceutics. – 2022. – № 14 (4). – P. 716. – DOIhttps://doi.org/10.3390/pharmaceutics14040716.
11. Diao L. Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides / L. Diao, B. Meibohm // Clinical Pharmacokinetics. – 2013. – № 52 (10). – P. 855–868. – DOI:https://doi.org/10.1007/s40262-013-0079-0.
12. Evaluation of Neuroprotective and Adjuvant Activities of Diketopiperazine-Based Peptidomimetics / V. Deigin, M. Premyslova, O. Ksenofontova et al. // Chemistry Select. 2023. – V. 8, № 8. – e202204076. – DOIhttps://doi.org/10.1002/slct.202204076.
13. Glu-Trp-ONa or its acylated analogue (R-Glu-Trp-ONa) administration enhances the wound healing in the model of chronic skin wounds in rabbits / M.A. Shevtsov, L.V. Smagina, T.A. Kudriavtceva et al. // Drug design, development and therapy. – 2015. – № 9. – P. 1717–1727. – DOI:https://doi.org/10.2147/DDDT.S79665.
14. Greening the synthesis of peptide therapeutics: an industrial perspective / V. Martin, P.H.G.Egelund, H. Johansson et al. // RSC Advances. – 2020. – № 10 (69). – P. 42457–42492. – DOI:https://doi.org/10.1039/d0ra07204d.
15. Introduction of D-Phenylalanine enhanced the receptor binding affinities of gonadotropinreleasing hormone peptides / J. Lu, H.J. Hathaway, M.E. Royce et al. // Bioorganic & Medicinal Chemistry Letters. – 2014. – № 24. – P. 725–730. – DOI:https://doi.org/10.1016/j.bmcl.2013.12.120.
16. Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries / L.V. Dergunova, I.B. Filippenkov, S.A. Limborska, N.F. Myasoedov // Genes. – 2023. – № 14. – P.953. – DOI:https://doi.org/10.3390/genes14050953.
17. Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center / A. Okada, Ushigome, M. Kanamori et al. // European Journal of Clinical Pharmacology. – 2017. – № 73 (9). – P. 1111–1119. – DOI:https://doi.org/10.1007/s00228-017-2279-2.
